Overdose crisis from illicit fentanyl mixed into heroin

The overdose crisis from illicit fentanyl mixed into heroin turned an already extensive heroin market in the Roanoke region into a more unpredictable and lethal one. In 2015, investigators recorded a sharp local warning: eleven overdose calls between May 1 and June 23, four of them fatal. The book presents fentanyl not as an isolated new danger but as a powerful synthetic drug entering a region where heroin was plentiful, families were often ashamed to seek help, and the criminal-justice and health-care systems left consequential gaps between them.

Emergence and scale

Six weeks after a local development described in the narrative, the region’s new HIDTA task force warned of a spike in opioid-overdose incidents. Its figures—eleven calls and four deaths in less than two months—gave the changing drug supply a stark local measure. Fentanyl had once been diverted from prescription patches used for advanced-cancer pain; it was now being illicitly imported and mixed with heroin or pressed into pills. Some shipments came directly from China, while others travelled through Mexico and, to a lesser extent, Canada.

The danger was compounded by fentanyl’s potency: the account describes it as twenty-five to fifty times stronger than heroin. Mail-order shipments were arriving at residences across the United States, along with pill presses used to convert powder into counterfeit tablets. One quarter-ton press reached Southern California in a package marked as a hole puncher. Cartel lieutenants were also establishing clandestine fentanyl laboratories in the United States, where powder could be mixed into heroin to intensify its effects. Products were stamped with names including China Girl, Goodfella, Jackpot, and Cash. The distinction between illicit suppliers and legitimate firms selling powder for pharmaceutical research could complicate efforts to intercept packages; envelopes might be labelled as research chemicals and carry false return addresses.

A changing and saturated market

Chris Perkins, then chief of the Roanoke Police Department, recognized fentanyl as a potential turning point. Because it could be snorted, he warned, new users might get high without injecting and without the visible track marks associated with injection. Counterfeit pills presented a separate risk: tablets sold as Xanax or oxycodone could actually contain fentanyl. The possibility that a person might encounter the drug without knowingly seeking it therefore sat alongside its appeal to people already using heroin.

That appeal could work against the warnings. People interviewed by the author said news of fentanyl-laced heroin deaths did not necessarily deter heroin users; some were drawn to the prospect of a stronger high. At the same time, the market’s volume made enforcement an unstable answer. Perkins said heroin was abundant, sold by former crack dealers diversifying their trade as well as by subdealers. In 2015, Roanoke police seized 560 grams—an amount the account equates to 18,666 doses or shots.

Perkins described the enforcement pattern as a more intense version of Whac-A-Mole: removing one source created only a short delay before another appeared, while overdoses continued. This pattern belonged to a broader local policing environment. Perkins had championed community policing, including officers engaging with teenagers in high-crime areas and using real-time data to refine where they worked. Since 2006, violent crime in the city had fallen by 64.5 percent and property crime by 39.9 percent. His 2011 Drug Market Initiative offered nonviolent offenders job training as an alternative to jail if they agreed to leave the drug trade. Those initiatives show that the narrative does not reduce policing to a single tactic, even as the fast-replenishing heroin supply reveals the limits of removing individual sellers.

Families, stigma, and treatment

The crisis unfolded in a region where stigma could isolate families as well as drug users. When reporting on heroin in the suburbs of Roanoke began in 2012, many families were too ashamed to speak publicly. In that year, parents in different parts of Virginia lacked Facebook groups through which they might have exchanged treatment advice, coping strategies, or practical and financial support. At a Families Anonymous meeting in a Lutheran church near Hidden Valley, two mothers met whose sons had become addicted first to pills and then to heroin. Their encounter linked families across social circles and exposed how people were trying to survive in the space between a health-care system and a criminal-justice system.

Medication could carry its own stigma within recovery settings. Tess Henry had attended twelve-step meetings but felt judged for taking buprenorphine. Although Narcotics Anonymous officially accepted medication-assisted treatment, longtime members asked to sponsor or mentor her politely declined. The account presents that rejection as a widening cultural divide over whether treatment with buprenorphine counted as being clean, rather than as a simple disagreement about individual preference. Such experiences matter in an overdose crisis: the availability of treatment does not guarantee that people will feel welcome in the settings meant to support recovery.

Public silence also constrained prevention. Janine Underwood brought her son’s story to local school-board and county officials, hoping to raise support for a risk-prevention council operating with limited funds. She had believed the Hidden Valley school zone offered her family protection, yet calls to the Hope Initiative came almost daily from Hidden Valley and nearby Cave Spring, and police data showed the problem was worse in those communities than in less affluent parts of the county. After Janine spoke, the school board declined to support the program and the county provided its usual $2,000. The contrast between the area’s relative affluence and the silence surrounding its drug problem illustrates how reputation and shame could impede recognition without preventing the crisis itself.

Earlier opioid failures and the limits of explanation

The book places the fentanyl danger against an earlier history of prescription-opioid expansion and disputed oversight. In the 1995 review of OxyContin’s application, the FDA’s Curtis Wright had information that crushing a tablet could release the drug immediately, that withdrawal symptoms had appeared in clinical trials, and that 68 percent of the oxycodone in a crushed pill could be recovered for injection. Purdue later claimed it had not known of abuse problems until February 2000. The narrative also describes private meetings between regulators and pharmaceutical executives beginning in 2002, and reports that a practice called enriched enrollment could exclude people who responded poorly to a drug from clinical studies. These details establish a record of concern about how opioid medicines were assessed and promoted; they do not make illicit fentanyl the same drug or, by themselves, establish a direct line from OxyContin to each fentanyl overdose.

The institutional context extended beyond the FDA. The American Pain Society and the American Academy of Pain Medicine advocated broader opioid use for long-term chronic pain while receiving millions from companies that manufactured opioids. Reporting on those ties prompted a 2012 Senate investigation that also examined the American Pain Foundation and Purdue, among other organizations and companies. The investigation’s results remained sealed in the Senate Finance Committee’s office. Set beside the local overdose calls and the difficulty of sustaining treatment and prevention, this unresolved record underscores the account’s larger concern: opioid harms develop across systems, while responsibility and remedies remain divided.

The crisis is therefore defined both by fentanyl’s lethal potency and by the conditions in which it spread. A supply that rapidly replenished itself could outpace seizures; a stronger drug could attract people despite reports of deaths; and stigma could make families, treatment, and public discussion harder to reach. The narrative’s recurring contrast is between the speed with which the drug market changed and the slower, fragmented response around it.